endpts.com·Apr 14, 2026
Biotech entrepreneur Michael Torres is selling his antibody-drug conjugate startup CrossBridge Bio to Eli Lilly for up to $300 million.
The acquisition of CrossBridge Bio by Eli Lilly for up to $300 million underscores the significant investment potential in antibody-drug conjugates within the biotech sector. As a professional in this field, consider monitoring startups focusing on this technology for potential partnerships or investments, as large pharmaceutical companies are actively seeking to enhance their pipelines through such strategic acquisitions.